News | April 27, 2023
Biocon approves NCD issue
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
Enabling clinical effectiveness via a fully interoperable and integrated digital pathology solution
Apollo continues to invest in genomics technology and research for better patient care
The USFDA had classified the inspection as "Official Action Indicated" (OAI).
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
The new team members, Solenn Percelay and Noémie Spinelli, will support the organization’s commitment to excellence in humanized mouse model care and use
Envelta is the company’s non-opioid pain product candidate for acute and chronic pain
Bourgoin early development hub broadens offerings for oral solid dose formulations
Venkat Nageswar Chalasani has been appointed as an Independent Director of Apitoria Pharma with effect from April 4, 2023
Extends patent protection for Microbion's proprietary inhaled pravibismane for the treatment of pulmonary infections to 2039
Subscribe To Our Newsletter & Stay Updated
